Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Progressive Corp (PGR) Price & Performance

Charles River Laboratories Intl. IncTrade
Progressive CorpTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Progressive Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $299.21 (market cap $14.23B), while Progressive Corp trades at $219.4 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 8.9× Charles River Laboratories Intl. Inc's market cap, and Progressive Corp pays a 0.18% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Progressive Corp for 81 Days on average.

CRLPGR
Market Cap
$14.23B$126.95B
Volume
1,176,8852,749,438
Sector
HealthFinancials
52-Week High
$310.77$242.16
52-Week Low
$149.93$190.40
Typical Hold Time
33 Days81 Days
Enterprise Value
$17.06B$135.16B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.

While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.

Progressive Corp

Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and robust profitability metrics including 34.94% ROE. Recent earnings show mixed results with Q2 2026 beating expectations while Q1 2026 missed. Analyst consensus leans neutral with 52.38% hold ratings but a $222.23 price target suggests modest upside potential from current levels.

PGR presents a balanced investment case with solid fundamentals and reasonable valuation (P/E 10.97) offset by competitive pressures in personal auto insurance. The stock's technical strength and consistent revenue growth support potential upside, though investors should monitor underwriting discipline amid intensifying market competition. Key risks include execution challenges and macroeconomic sensitivity affecting insurance demand.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRL
0% Buy100% Sell
Avg holding period · 33 Days
PGR
3% Buy97% Sell
Avg holding period · 81 Days

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL →

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR →